Sandoz’ EpiPen rival will launch in Q1, with lower price tag

10-Dec-2018 - Last updated on 12-Aug-2019 at 17:43 GMT

(Image: Getty/CarrieCaptured)

Sandoz will launch its epinephrine generic in early 2019 at a lower price point than rival generics on the market.

Sandoz, a division of Novartis, has updated its launch plans of Sympjepi (epinephrine) .3mg pre-filled single dose injection in the US; the injection will be available for the emergency treatment of allergic reactions, including anaphylaxis, in early Q1 2019.

The company stated that it is actively preparing to bring the product to the US market. With manufacturing already completed, it is well underway to establish an appropriate supply of the medicine for healthcare professionals and patients.

Sandoz set its planned wholesale cost for a two-pack of Sympjepi at $250 (€218), while Mylan’s and Teva’s authorized generic EpiPen products both retail for $300.

Manufacturing of Teva’s generic began in August, following regulatory approval and will be in limited supply in the US upon launch.

Prices for the commonly prescribed EpiPen have been a subject of discussion, even at the level of US Congress. In 2016, US Congress asked the US Food and Drug Administration for information on EpiPen generic submissions and processes, after Mylan increased its prices – that year, prices of the life-saving allergy drug-device increased by a total of 548%.